This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Idiopathic Pulmonary Fibrosis특발성 폐섬유증 (특발성폐섬유증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: J84.1 | Special Copayment Reduction: V236
B. Synonyms—
C. Adult onsetLikelihood of first onset in adulthood very high — by definition, IPF occurs in adults aged 50 and older, with a mean age at diagnosis of 65–70 years. Onset before age 50 is extremely rare, and it virtually does not occur in children and adolescents.
1. History1890s, von Buhl's description of pulmonary induration → 1944, Hamman-Rich cases of acute progressive pulmonary fibrosis → 1999, unified ATS/ERS definition of IPF → 2011, HRCT diagnostic criteria based on the UIP pattern established → 2014, FDA approval of pirfenidone and nintedanib.
2. CausesUnknown cause (idiopathic). Risk factors: smoking (the strongest), gastroesophageal reflux, chronic viral infection, occupational dust (metal, wood, agricultural), air pollution, advanced age. Abnormal fibrotic response after repeated alveolar epithelial injury is the core hypothesis.
3. GeneticsAbout 2–5% are familial. The MUC5B promoter variant (rs35705950) is the most common risk factor in both sporadic and familial IPF. Associated with short-telomere-related genes TERT, TERC and RTEL1 and with variants of the surfactant genes SFTPC and SFTPA2.
4. General epidemiologyPrevalence 14–43 per 100,000 population (regional differences). Annual incidence about 3–9 per 100,000. Male > female (about 1.5–2:1). Incidence highest in the 70s. Korea: steadily increasing trend based on health insurance data. Eligible for Special Copayment Reduction registration under V236.
5. PathophysiologyRepeated injury of alveolar type 2 epithelial cells → abnormal epithelial-mesenchymal transition → activation and accumulation of myofibroblasts → excessive deposition of extracellular matrix (collagen) → destruction of normal lung architecture and honeycomb remodeling → impaired gas exchange.
6. SymptomsSlowly progressive exertional dyspnea, dry cough (throat-irritating). Average delay of 1–2 years from symptom onset to diagnosis. In acute exacerbation (AE-IPF), rapid worsening of dyspnea within days to weeks. Accompanied by fatigue and weight loss.
7. SignsBilateral basal velcro crackles (most characteristic). Clubbing (about 25–50%). Cyanosis (with progression). Hypoxemia. HRCT: bilateral basal, subpleural honeycombing + traction bronchiectasis is the typical UIP pattern.
8. ScreeningNo screening of the general population. In smokers aged 65 and older with persistent dyspnea or cough, early chest HRCT. First-degree relatives in families with familial IPF: consider follow-up pulmonary function tests and HRCT regardless of symptoms. Elevated serum KL-6 and SP-D for reference.
9. DiagnosisAfter confirming a UIP/probable UIP pattern on chest HRCT, exclude secondary causes (CTD, drugs, occupational exposure). Typical UIP + clinical information allows diagnosis without surgical biopsy. Atypical pattern: surgical lung biopsy (confirm UIP histologic pattern). Multidisciplinary discussion recommended.
10. TreatmentAntifibrotics: pirfenidone or nintedanib. Lung transplantation (selected patients). Supplemental oxygen. Pulmonary rehabilitation. Acute exacerbation: high-dose steroids (limited evidence). Symptom relief: antitussives, treatment of acid reflux, concurrent treatment when pulmonary hypertension is present.
11. PrognosisMedian survival after diagnosis about 2.5–3.5 years. 5-year survival about 20–40%. Pirfenidone and nintedanib slow the rate of FVC decline by about 50%. In-hospital mortality 40–60% when acute exacerbation occurs. 5-year survival after lung transplantation about 50–55%.
12. PreventionSmoking cessation (most important). Prevention of occupational dust exposure. Treatment of gastroesophageal reflux. Genetic counseling in familial IPF. Influenza and pneumococcal vaccination. Early antifibrotic therapy to suppress progression.
13. ReferencesRaghu G et al. An Official ATS/ERS/JRS/ALAT Statement: IPF. Am J Respir Crit Care Med. 2011 … and 9 other references

1. History

The history of Idiopathic Pulmonary Fibrosis (IPF) dates back to the late 19th century. One of the early records is the pathological description of progressive induration of the lung by the German pathologist Georg Ernst von Buhl in 1892. In 1944, Louis Hamman and Arnold Rich in the United States reported 4 cases of acute progressive pulmonary fibrosis leading to death within weeks to months. These cases later became known as "Hamman-Rich syndrome", but are now reclassified as acute interstitial pneumonia (AIP) or acute exacerbation of IPF.

In the 1950s–1960s, Averill Liebow introduced the concept of 'usual interstitial pneumonia (UIP)' while histologically classifying interstitial lung diseases. UIP later came to be recognized as the histologic pattern of IPF. In the 1970s–1980s, steroid treatment was tried but had limited efficacy, and from this period awareness began to grow that IPF is a fibrosis-centered disease rather than an immune-mediated one.

In 1999, the American Thoracic Society (ATS) and the European Respiratory Society (ERS) jointly published an international consensus statement on IPF, unifying its definition, diagnostic criteria and classification. In 2002, a revised statement included the UIP pattern on high-resolution CT (HRCT) in diagnosis, laying the groundwork for clinical diagnosis without tissue biopsy in patients with a typical UIP CT pattern.

In the 2011 joint ATS/ERS/JRS (Japanese Respiratory Society)/ALAT (Latin American Thoracic Association) guideline, the diagnostic criteria for IPF were further refined; HRCT findings of the UIP pattern were specifically defined, and multidisciplinary discussion (MDD) was integrated into the diagnostic process.

The most important advance in treatment came in 2014. The antifibrotic pirfenidone, developed in Japan, and nintedanib, developed by Boehringer Ingelheim of Germany, each demonstrated significant slowing of FVC decline in large phase 3 trials (CAPACITY·ASCEND and INPULSIS) and received FDA approval. These two drugs changed the paradigm of IPF treatment and are currently used worldwide as first-line agents. The subsequently revised 2022 ATS/ERS/JRS/ALAT guideline presents both drugs at the level of a conditional recommendation in patients with IPF.


2. Causes

By definition, idiopathic pulmonary fibrosis is a chronic progressive fibrosing interstitial pneumonia of unknown cause. However, epidemiologic studies have identified several risk factors, and these risk factors are understood to cause repeated alveolar epithelial injury and trigger an abnormal fibrotic response in genetically predisposed individuals.

Smoking is the strongest risk factor for IPF; about 60–70% of patients are current or former smokers. Tobacco smoke causes oxidative stress and injury to alveolar type 2 epithelial cells, triggering the fibrotic process. The risk of IPF rises as smoking exposure (pack-years) increases. Secondhand smoke has also been suggested as a risk factor.

Gastroesophageal reflux (GERD) can cause repeated alveolar injury through microaspiration. Asymptomatic GERD is observed in about 80–90% of patients with IPF. Studies on the effect of acid suppression therapy on IPF prognosis are ongoing, but including antireflux treatment in standard care is currently recommended.

Occupational dust exposure: occupational exposure to metal dust (especially brass, lead, steel), wood dust, agricultural dust and stone dust increases the risk of IPF. Asbestos exposure causes fibrotic lung disease, but it is separately classified as asbestosis rather than typical IPF and must be excluded as a secondary cause.

Viral infection: Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpesviruses, post-COVID-19 fibrosis, etc. are being studied as triggers in IPF pathogenesis. It has been hypothesized that repeated alveolar injury due to chronic viral infection may be one of the environmental triggers of IPF.

Advanced age: IPF is very rare before age 50 and shows the highest incidence in the 70s. Age-related decline in alveolar epithelial regenerative capacity, telomere shortening and aging-related immune changes are explained as increasing susceptibility to fibrosis.


3. Genetics

About 2–5% of idiopathic pulmonary fibrosis is familial IPF (FIP), defined as two or more affected first- or second-degree relatives. Familial IPF is clinically and histologically similar to sporadic IPF and tends to show an earlier age of onset (10–15 years earlier). The inheritance pattern of familial IPF is mainly autosomal dominant, but penetrance is low (30–60%).

MUC5B promoter variant (rs35705950): the most important genetic risk factor for IPF, markedly increasing risk in both familial and sporadic IPF (OR 6–9). MUC5B encodes a mucin protein, and this variant leads to overexpression of MUC5B in the lung, creating an abnormal mucus environment that may promote impaired regeneration after epithelial injury. However, because this variant is also common in sporadic IPF, it is not used as a stand-alone diagnostic tool.

Telomere-related genes: variants in TERT (telomerase reverse transcriptase), TERC (telomerase RNA component), RTEL1, PARN and others cause telomere shortening, promoting senescence and impaired regeneration of the alveolar epithelium. These variants are found in about 25% of familial IPF and about 3% of sporadic IPF. Telomere shortening is studied as a major mechanism of reduced alveolar epithelial regenerative capacity and delayed tissue injury.

Surfactant genes: specific variants of SFTPC (SP-C) and SFTPA2 (SP-A2) are also associated with familial IPF. These variants are understood to promote endoplasmic reticulum stress (ER stress) and injury to alveolar type 2 epithelial cells. ABCA3 variants are also rarely associated with familial IPF.

Genetic testing (telomere length measurement, gene panel analysis) and genetic counseling are recommended for patients with familial IPF and their first-degree relatives. Patients with telomere-related gene variants may have systemic phenotypes such as bone marrow failure, liver cirrhosis and skin pigmentation, and recognizing this clinically is important. Gene-based treatment strategies for IPF are currently at the research stage.


4. General epidemiology

Idiopathic pulmonary fibrosis is a rare chronic lung disease; its worldwide prevalence is reported as about 14–43 per 100,000 population and its annual incidence as about 3–9, but there are large differences depending on diagnostic criteria and region. Incidence tends to be higher in North America and Europe than in Asia and Africa, but this may reflect differences in diagnostic access and awareness.

Sex and age distribution: it occurs about 1.5–2 times more often in men than in women. This may be related to sex differences in smoking rates and occupational exposure. Onset before age 50 is very rare, and incidence increases with age, peaking in the 70s.

Increasing incidence trend: a worldwide increasing trend in the incidence of IPF has been reported over recent decades. Population aging, improved diagnostic awareness and changes in diagnostic criteria contribute in combination. In Korea as well, a study based on Health Insurance Review & Assessment Service (HIRA) data reported that the number of patients diagnosed with IPF increased continuously between 2007 and 2018.

Epidemiology in Korea: in Korea, IPF is eligible for rare disease Special Copayment Reduction registration (V236), and the actual number of patients in Korea is estimated at several thousand or more based on health insurance data. Smoking, advanced age and male sex have also been confirmed as major risk factors in Korean patients with IPF. The median survival of Korean patients with IPF is reported to be similar to that of Western cohorts.

Comorbidities: in patients with IPF, pulmonary hypertension (present in about 30–40% of patients with IPF), lung cancer (about 3–7 times higher risk than the general population), pulmonary embolism, cardiovascular disease, gastroesophageal reflux and sleep apnea occur at high frequency. Management of these comorbidities affects the overall clinical course of IPF.


5. Pathophysiology

The pathophysiology of idiopathic pulmonary fibrosis is understood as repeated alveolar epithelial injury and an abnormal response to it. In the past, chronic inflammation was considered the core mechanism, but now abnormal alveolar epithelial-mesenchymal interaction is understood to be central, which is supported by the lack of efficacy of anti-inflammatory treatment in IPF.

Alveolar epithelial injury: alveolar type 2 epithelial cells (ATII) are repeatedly injured by various triggers such as smoking, gastric acid microaspiration, viral infection, aging and genetic susceptibility. Injured ATII cells develop endoplasmic reticulum stress (ER stress), mitochondrial dysfunction, cellular senescence due to telomere shortening and abnormal apoptosis. These cells emit profibrotic signals instead of the normal regeneration needed for basement membrane reconstruction.

Myofibroblast activation: injured epithelial cells secrete TGF-β1 (transforming growth factor), PDGF (platelet-derived growth factor), FGF (fibroblast growth factor) and others, activating nearby fibroblasts into myofibroblasts. Myofibroblasts synthesize excess collagen and extracellular matrix (ECM) proteins and express αSMA (α-smooth muscle actin), giving them mechanical contractility. Unlike in normal tissue regeneration, these cells remain in an activated state and sustain self-amplifying fibrosis.

Wnt/β-catenin and Hedgehog signaling pathways: the Wnt/β-catenin and Sonic Hedgehog (Shh) signaling pathways, which are active during embryonic development, are studied as being reactivated in the IPF lung, promoting fibroblast-to-myofibroblast transition and ECM synthesis.

Honeycombing: sustained ECM accumulation destroys alveolar architecture, forming dilated cystic spaces (honeycombing) and traction bronchiectasis. These structural changes are irreversible and sharply reduce the gas exchange surface. Progressive destruction of alveolar-capillary units results in hypoxemia, pulmonary hypertension and right heart failure.

Endothelial cells and vascular remodeling: in IPF, abnormal angiogenesis of the pulmonary microvasculature is observed, and abnormal vascular distribution worsens hypoxia of lung tissue. Nintedanib works by inhibiting the PDGFR, VEGFR and FGFR tyrosine kinases, blocking these vascular and fibrotic pathways.


6. Symptoms

The clinical symptoms of idiopathic pulmonary fibrosis follow a slowly progressive chronic course, and considerable loss of lung function is often already present at diagnosis. An average delay of 1–2 years from symptom onset to diagnosis is reported.

Progressive exertional dyspnea is the most common and characteristic symptom, occurring in about 80–90% of patients. Initially it appears only when climbing stairs or walking fast, but as the disease progresses it occurs even with light daily activities or at rest. Because dyspnea progresses slowly, patients often underestimate the symptom while naturally reducing their level of daily activity.

Dry cough is the second most common symptom, occurring in about 60–80% of patients. It is characterized by a throat-irritating dry cough with no or little sputum. The cough persists at night, disturbing sleep and reducing quality of life. In some patients, cough becomes a major symptom that severely limits social activity.

Acute exacerbation (AE-IPF): about 10–15% of patients with IPF experience an unexplained acute exacerbation each year. Triggers such as infection, surgery or bronchoscopy are identified in some cases, but in many cases it occurs without a clear cause (idiopathic AE-IPF). Severe dyspnea and a rapid increase in oxygen requirement appear within days to weeks, and hospitalization and mechanical ventilation are often required.

Fatigue, weight loss and anorexia appear as systemic symptoms and are more prominent in advanced IPF. Reduced exercise capacity and social isolation also have important effects on quality of life. Sleep disturbance and depressed mood are also commonly present.

When pulmonary hypertension is present, orthopnea, lower extremity edema and chest pain may be added. When lung cancer is present, hemoptysis, chest pain and weight loss may be prominent.


7. Signs

The physical findings of idiopathic pulmonary fibrosis are relatively characteristic and help differentiate it from other interstitial lung diseases.

Bilateral basal inspiratory crackles (velcro crackles): the most characteristic physical finding of IPF. Velcro-like crackles are heard in both lower lung fields at end-inspiration and resemble the sound of velcro tape being pulled apart. This finding is identified in about 70–80% of patients. Initially they appear only at the bases, spreading upward with progression.

Digital clubbing: a characteristic finding present in about 25–50% of patients with IPF, more common in IPF than in other interstitial lung diseases (especially hypersensitivity pneumonitis, NSIP). Chronic hypoxemia and abnormal secretion of growth factors are suggested as mechanisms.

Pulmonary function tests: characterized by a restrictive ventilatory defect (reduced FVC, normal or increased FEV₁/FVC) and reduced diffusing capacity (DLCO). In smokers, an obstructive ventilatory defect (COPD) may overlap, giving a mixed pattern. The rate of FVC decline (annual %FVC decline) is a key indicator for assessing prognosis and treatment response.

Chest HRCT findings: the usual interstitial pneumonia (UIP) pattern is the typical imaging finding of IPF. Bilateral, basal-predominant, subpleural honeycombing and traction bronchiectasis are characteristic. Ground-glass opacity is typically less than honeycombing or absent. In the 'Probable UIP' pattern, only traction bronchiectasis without honeycombing may be present.

Serum biomarkers: serum KL-6 (Krebs von den Lungen-6) and SP-D (surfactant protein D) are markers of alveolar type 2 epithelial cell injury; they are elevated in IPF and used as adjuncts for disease activity and prognosis prediction. However, their specificity as stand-alone diagnostic tools is low.


8. Screening

There is no systematic screening program for idiopathic pulmonary fibrosis in the general population. However, early recognition and diagnosis in high-risk groups are important.

Symptom-based early testing: in smokers aged 50 and older (especially men) with unexplained exertional dyspnea or dry cough lasting 3 months or longer, chest HRCT is performed early. If bilateral basal ground-glass or reticular opacities are found on plain chest X-ray, proceed to HRCT immediately. Because diagnostic delay often results from poor recognition of IPF in primary care, early referral to a pulmonologist is recommended.

Screening in families with familial IPF: in families with two or more patients with IPF, experts recommend regular follow-up screening including HRCT and pulmonary function tests for asymptomatic first-degree relatives (aged 50 and older). In carriers of telomere-related gene variants, follow-up may be needed from an earlier age.

Serum KL-6 and SP-D: these biomarkers are used clinically in some countries (especially Japan) as screening tools for interstitial lung disease. They do not diagnose IPF on their own, but serve to prompt further testing (HRCT) in suspected patients.

Pulmonary function tests: regular pulmonary function testing including FVC and DLCO in high-risk groups may be useful for detecting an early restrictive pattern of interstitial lung disease. An annual FVC decline of 5% or more or a DLCO decline of 15% or more is considered a clinically meaningful loss of lung function.


9. Diagnosis

The diagnosis of idiopathic pulmonary fibrosis is based on exclusion of secondary causes (connective tissue disease, drug toxicity, occupational exposure, etc.) and confirmation of a typical UIP pattern. Multidisciplinary discussion (MDD) is important for increasing diagnostic accuracy.

Exclusion of secondary causes: causes that must be excluded before diagnosing IPF include connective tissue diseases (rheumatoid arthritis, Sjögren syndrome, systemic sclerosis, polymyositis/dermatomyositis, mixed connective tissue disease), drug-induced lung disease (amiodarone, methotrexate, nitrofurantoin, chemotherapeutic agents, etc.), hypersensitivity pneumonitis (HPSens) and occupational dust exposure. Autoantibody tests such as antinuclear antibody (ANA), rheumatoid factor (RF), anti-CCP antibody, anti-Jo-1 antibody and anti-Scl-70 antibody are essential for differentiating connective tissue diseases.

Chest HRCT: classified as UIP pattern (typical UIP: bilateral basal subpleural honeycombing ± traction bronchiectasis), Probable UIP, Indeterminate for UIP and non-UIP pattern. Under the 2018 ATS/ERS guideline, a clinical diagnosis of IPF without tissue biopsy is possible in patients aged 50 and older with a typical or probable UIP HRCT pattern when secondary causes are excluded.

Surgical lung biopsy: performed when the diagnosis is uncertain with an Indeterminate or non-UIP HRCT pattern. Video-assisted thoracoscopic (VATS) lung biopsy obtains tissue from multiple lobes to confirm the UIP histologic pattern (temporal heterogeneity, fibroblastic foci, honeycomb change). In patients at high surgical risk due to advanced age, reduced lung function, pulmonary hypertension, etc., transbronchial cryobiopsy (TBLB) is used as a less invasive alternative.

Bronchoalveolar lavage (BAL): in IPF, BAL is performed not to confirm the diagnosis but to exclude secondary causes (lymphocytosis of hypersensitivity pneumonitis, eosinophilia of eosinophilic pneumonia, exclusion of infection, etc.). In IPF, BAL shows nonspecific findings of a mild increase in neutrophils and sometimes eosinophils.

Blood tests: include complete blood count, biochemistry, autoantibody panel (ANA, RF, anti-CCP, anti-Jo-1, anti-MDA5, anti-Scl-70, anti-SS-A/SS-B), thyroid function tests, serum KL-6 and SP-D, low-titer precipitating antibodies (bacterial antigens), etc. If a first-degree relative has IPF, genetic testing (telomere length measurement, gene panel testing) is considered.


10. Treatment

The goals of treatment of idiopathic pulmonary fibrosis are to slow disease progression, prevent acute exacerbations and relieve symptoms to maintain quality of life. There is currently no cure for IPF, and lung transplantation is the only definitive treatment.

Antifibrotic — pirfenidone: the exact mechanism of action has not been fully elucidated, but it is known to inhibit TGF-β signaling, cell proliferation and collagen synthesis. In the CAPACITY (EU) and ASCEND (US) trials, it slowed the rate of FVC decline by about 50%. The standard dose is 801 mg three times daily (total 2,403 mg/day), and gastrointestinal upset and photosensitivity are the main adverse effects. Taking it with meals and sun protection are recommended.

Antifibrotic — nintedanib: a PDGFR, VEGFR and FGFR tyrosine kinase inhibitor that reduced the annual rate of FVC decline by about 50% in the INPULSIS trials. The standard dose is 150 mg twice daily; diarrhea and nausea are the main adverse effects, and concomitant antidiarrheal (loperamide) use helps. It is contraindicated in pregnancy or in women who may be pregnant.

Lung transplantation: the only treatment that prolongs survival in patients with IPF that progresses despite antifibrotics. The 5-year survival after lung transplantation is about 50–55%, and IPF is one of the most common indications for lung transplantation. Because transplant waiting times are long, early referral to a transplant center is recommended. Some studies suggest that bilateral lung transplantation may be superior to single lung transplantation in survival.

Supplemental oxygen therapy: long-term oxygen therapy is recommended when SpO₂ ≤88% at rest or when there is exertional hypoxemia. Nocturnal hypoxemia is also monitored and nocturnal oxygen supplementation is considered.

Pulmonary rehabilitation: randomized controlled trials have confirmed its effectiveness in improving exercise tolerance, reducing dyspnea and improving quality of life. Participation in a pulmonary rehabilitation program (exercise training, breathing education, nutritional counseling) is recommended for all patients with IPF.

Treatment of acute exacerbation (AE-IPF): high-dose corticosteroids (methylprednisolone 500–1,000 mg/day) are used clinically, but evidence from randomized controlled trials is lacking. Because outcomes of mechanical ventilation in AE-IPF are very poor, it should be used with caution except in patients awaiting lung transplantation. ECMO is used in some centers as a bridge to lung transplantation.


11. Prognosis

Idiopathic pulmonary fibrosis is a disease with an overall poor prognosis; median survival after diagnosis is reported as about 2.5–3.5 years and 5-year survival as about 20–40%. This is a worse prognosis than some lung cancers, but individual prognosis is highly heterogeneous.

Prognostic factors: FVC (% predicted) and DLCO (% predicted) at diagnosis, exertional oxygen desaturation, the extent of honeycombing on HRCT, 6-minute walk distance, etc. are important prognostic indicators. An annual FVC decline of 10% or more or a DLCO decline of 15% or more is a strong predictor of increased risk of death. Concomitant pulmonary hypertension markedly worsens prognosis.

Prognostic effect of antifibrotics: pirfenidone and nintedanib slow the rate of FVC decline by about 50%, suppressing disease progression, but cannot reverse fibrosis that has already formed. Trial results show that both drugs statistically significantly reduced IPF-related death or the occurrence of acute exacerbations. Analyses of long-term effects in real-world clinical settings also observe a survival benefit in patients treated with antifibrotics.

Prognostic impact of acute exacerbation: AE-IPF is a fatal complication with in-hospital mortality reaching 40–60%. The median survival of patients who have experienced AE-IPF is only weeks to months.

Prognosis after lung transplantation: lung transplantation improves the 5-year survival of IPF to about 50–55%. Chronic lung allograft dysfunction (CLAD), infection and rejection are the main complications after transplantation. In interstitial lung diseases including IPF, bilateral lung transplantation tends to show better outcomes than single lung transplantation.

Management of comorbidities: actively managing comorbidities such as pulmonary hypertension, lung cancer and gastroesophageal reflux is important for improving the overall prognosis of IPF. Palliative care plays a key role in symptom management, psychosocial support and linkage to hospice for patients with advanced IPF.


12. Prevention

There is currently no way to completely prevent the development of idiopathic pulmonary fibrosis. However, control of known risk factors and early diagnosis in high-risk groups are important for suppressing disease progression.

Smoking cessation is the strongest and most feasible strategy for preventing IPF. Because smoking is the most established risk factor for the development of IPF, remaining a nonsmoker or quitting early is recommended at all ages. Direct evidence on whether smoking cessation helps suppress disease progression in patients with IPF who smoke is limited, but it is strongly recommended for general lung health.

Prevention of occupational dust exposure: occupational hygiene measures to minimize exposure to metal, wood, stone and agricultural dust (dust masks, ventilation facilities, exposure monitoring) contribute to the prevention of secondary pulmonary fibrosis.

Treatment of gastroesophageal reflux: observational studies suggest that treating gastroesophageal reflux, including asymptomatic GERD, may help suppress IPF progression. Use of proton pump inhibitors (PPIs) is recommended in patients with IPF, but confirmation in large randomized trials is ongoing.

Vaccination: preventing AE-IPF caused by respiratory infection through influenza and pneumococcal vaccination is important. COVID-19 vaccination is also strongly recommended for patients with IPF.

Genetic counseling and screening in familial IPF: in families with familial IPF, genetic counseling and genetic testing are offered to first-degree relatives, and risk factor control (smoking cessation, etc.) and regular follow-up tests (pulmonary function, HRCT) provide opportunities for early diagnosis.

Early antifibrotic therapy: starting an antifibrotic (pirfenidone or nintedanib) immediately upon diagnosis is the most effective strategy for suppressing disease progression. The latest guidelines emphasize starting treatment without delay even when symptoms are mild or lung function is preserved.


13. References

  1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824. DOI: 10.1164/rccm.2009-040GL. PMID: 21471066.

  2. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44-e68. DOI: 10.1164/rccm.201807-1255ST. PMID: 30168753.

  3. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis (ASCEND). N Engl J Med. 2014;370(22):2083-2092. DOI: 10.1056/NEJMoa1402582. PMID: 24836312.

  4. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis (INPULSIS). N Engl J Med. 2014;370(22):2071-2082. DOI: 10.1056/NEJMoa1402584. PMID: 24836310.

  5. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431-440. DOI: 10.1164/rccm.201006-0894CI. PMID: 20935110.

  6. Cottin V, Wollin L, Fischer A, et al. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. 2019;28(151):180100. DOI: 10.1183/16000617.0100-2018. PMID: 30872396.

  7. Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med. 2008;5(3):e62. DOI: 10.1371/journal.pmed.0050062. PMID: 18336067.

  8. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364(16):1503-1512. DOI: 10.1056/NEJMoa1013660. PMID: 21506741.

  9. Lim SY, Song JW. IPF in Korean patients: clinical characteristics and outcomes. Respir Med. 2018;140:45-52. DOI: 10.1016/j.rmed.2018.05.017. PMID: 29866307.

  10. Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis: an international working group report. Am J Respir Crit Care Med. 2016;194(3):265-275. DOI: 10.1164/rccm.201604-0801CI. PMID: 27299520.